다모라 테라퓨틱스(DMRA) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

DMRA

Damora Therapeutics Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$29.41

+0.59 ▲ +2.05%

🌙 7월 27일 7:34 PM ET (한국 7/28 08:34)

$29.44

+0.00 +0.00%

다모라 테라퓨틱스(DMRA) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1.8B

스몰캡

P/E

배당수익률

없음

52주 위치

75%

저점 +1100% · 고점 -23%

애널리스트

적극 매수

C+

Fundamental health

vs. 성장주 소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 71%

밸류에이션

데이터 부족

재무 안정

Top 33%

Index ⓘ	RUT	P/E ⓘ	-	EPS (ttm) ⓘ	-126.87	Insider Own ⓘ	25.3%	Shs Outstand ⓘ	60.3M	Perf Week ⓘ	-10.85%
Market Cap ⓘ	1.81B	Forward P/E ⓘ	-	EPS next Y ⓘ	-6.93%	Insider Trans ⓘ	-	Shs Float ⓘ	46.0M	Perf Month ⓘ	30.31%
Enterprise Value ⓘ	1.41B	PEG ⓘ	-	EPS next Q ⓘ	-0.42	Inst Own ⓘ	74.28%	Short Float ⓘ	10.19%	Perf Quarter ⓘ	18.83%
Income ⓘ	-0.24B	P/S ⓘ	-	EPS this Y ⓘ	51.24%	Inst Trans ⓘ	177.54%	Short Ratio ⓘ	8.13	Perf Half Y ⓘ	14.17%
Sales ⓘ	0.00B	P/B ⓘ	4.68	EPS next 5Y ⓘ	14.39%	ROA ⓘ	-85.36%	Short Interest ⓘ	4.69M	Perf YTD ⓘ	27.81%
Book/sh ⓘ	6.29	P/C ⓘ	3.4	EPS past 3/5Y ⓘ	-36.14% -34.72%	ROE ⓘ	-89.97%	52W High ⓘ	-23.26% ($38.33)	Perf Year ⓘ	684.27%
Cash/sh ⓘ	8.66	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-	ROIC ⓘ	-45.95%	52W Low ⓘ	1100.41% ($2.45)	Perf 3Y ⓘ	-61.3%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-721.01%	Gross Margin ⓘ	-	Volatility(W/M) ⓘ	9.3% 10.11%	Perf 5Y ⓘ	-72.25%
Dividend TTM ⓘ	-	EV/Sales ⓘ	-	Sales Y/Y TTM ⓘ	-	Oper. Margin ⓘ	-	ATR (14) ⓘ	2.54	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	22.48	EPS Q/Q ⓘ	57.77%	Profit Margin ⓘ	-	RSI (14) ⓘ	53.8	Recom ⓘ	1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	22.48	Sales Q/Q ⓘ	-	SMA20 ⓘ	-0.13% ($29.45)	Beta ⓘ	1.47	Target Price ⓘ	$44.11
Payout ⓘ	-	Debt/Eq ⓘ	0	Earnings ⓘ	2026/5/12	SMA50 ⓘ	14.96% ($25.58)	Rel Volume ⓘ	0.95	Prev Close ⓘ	$28.82
Employees ⓘ	7	LT Debt/Eq ⓘ	0	EPS/Sales Surpr. ⓘ	-59.88% -	SMA200 ⓘ	25.49% ($23.44)	Avg Volume(3M) ⓘ	0.58M	Price ⓘ	$29.41
IPO ⓘ	2020/10/29	Option/Short ⓘ	No/Yes			Trades ⓘ	5346	Volume ⓘ	547,183	Change ⓘ	2.05%

Quarterly earnings trend SEC filings · USD

23.9

24.3

24.6

24.9

25.3

25.6

25.9

26.3

Revenue Net income 최근 분기: 매출 - · 순이익 $-28M (YoY -997%)

📊 Damora Therapeutics Inc (DMRA) Investment Analysis

What kind of company is Damora Therapeutics Inc?

다모라 테라퓨틱스(DMRA) 성장주

Healthcare · Biotechnology

Healthcare Stocks

🩸 Damora Therapeutics (DMRA) is a US biotech company developing antibody therapies targeting mutant calreticulin (mutCALR). The company has a differentiated pipeline for patients with myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis, and has changed its name from Galecto to focus on treating blood disorders.

Learn more about Damora Therapeutics Inc →

Market Cap

$1.8B

Approx. KRW 2.5 trillion

⚖️ 1% of Samsung Electronics

Market Cap Rank2192

Employees7people

IPO2020/10/29

Current Price$29.41 ≈ 40,292원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 12일 (화) · 장 마감 후 EPS -59.9%

🔔 Earnings release 2026년 3월 19일 (목) · 장 마감 후 EPS -459.5%

Is it profitable?

Financially sound but profitability is low

Losses or thin margins — early-stage growth or weakening competitiveness

Profitability — How efficiently it makes money

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-90.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-85.4%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROIC

Return generated per dollar invested in the business

-46.0%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.00

✓ Very low debt

My positionTop 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

22.48

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

22.48

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$44.11

현재가 대비 +50.0%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

내년 EPS 예상 성장률

-6.9%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+14.4%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-259.7%

평균 서프라이즈

2026.05.12

하회

-59.9%

2026.03.19

하회

-459.5%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+51.2%

우수

My positionTop 5%

Low range Average High range

성장주 소형주 Median 16.2% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-6.9%

매우 부진

My positionBottom 5%

Low range Average High range

성장주 소형주 Median 17.5% · Bottom tier

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+14.4%

평균

My positionMid-range

Low range Average High range

성장주 소형주 Median 18.9% · Bottom 26%

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-36.1%

부진

My positionBottom 25%

Low range Average High range

성장주 소형주 Median 8.7% · Bottom 11%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-34.7%

부진

My positionBottom 25%

Low range Average High range

성장주 소형주 Median 2.9% · Bottom 11%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -141%p below the market

DMRA -72.3% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-140.6%p

Significantly behind the market

vs Health Care (XLV)

-96.8%p

Significantly behind the sector average

1-year basis

vs S&P 500

+668.3%p

well ahead of the market

vs Health Care (XLV)

+664.5%p

well ahead of the sector average

Rank among peers

5-year return Lower-Mid (lower 36%) Based on 123 peers

1-year return Top among peers Based on 154 peers

Current position within 52-week range

Low (-1100.4%p) High (-23.3%p)

Current price is 1100.4% above the 52-week low and 23.3% below the 52-week high

Recent risk (last 96 trading days)

Max drawdown

-31.2%

Annualized volatility

82.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-27

Downtrend zone

Current price $29.41 below the midline ($29.44). Normal downward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 1.439 · Signal 1.735 · Hist -0.296. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 53.8 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 36.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

In line with peers on Vs. Assets

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🏢 Vs. Assets Mid-range

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

4.68x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 3.34x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

Analyst target price (reference)

$44.11 vs. current price +50.0%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership is broadly stable

Institutional net buying +177.5% · Short interest elevated 10.2% · Short interest up +9.7pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

+177.5%

Institutions large net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 74.3%

Adequate institutional weight

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 25.3%

Founder/management large holders (strong skin-in-the-game)

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 0.4%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

10.2%

Somewhat high

Healthcare 소형주 Median 11.2%

Past 90 days 📈 +9.7%p increase

Short interest days to cover

8.1 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 60.3M주

Float (tradable shares) 46.0M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding DMRA

ETFs with the highest weightings · 5 total shown

FFSM

Fidelity Fundamental Small-Mid Cap ETF

0.07%

$1.5B

LABU

Direxion Daily S&P Biotech Bull 3X ETF

0.03%

$546M

XBI

State Street SPDR S&P Biotech ETF

0.03%

$10.0B

VXF

Vanguard Extended Market Index ETF

0.01%

$30.4B

ONEQ

Fidelity Nasdaq Composite Index ETF

0.00%

$10.2B

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
DMRA This Stock	$1.8B	-	4.7 ▼	-89.97% ▼	-	+2.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 다모라 테라퓨틱스(DMRA)?

다모라 테라퓨틱스(DMRA) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of DMRA?

The market cap of DMRA is approximately $1.8B, ranking 2,192 within its sector.

What is the 52-week high and low for DMRA?

DMRA has recorded a 52-week high of $38.33 and a low of $2.45.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.